Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
G-CSF (Granulocyte Colony Stimulating Factors) Market Growth Potential: How Will Market Size Shift Through 2030?
The g-csf (granulocyte colony stimulating factors) market has shown consistent expansion in recent years. It is projected to increase from $9.48 billion in 2025 to $9.94 billion in 2026, at a compound annual growth rate (CAGR) of 4.8%. This historical growth can be attributed to factors such as the limited availability of g-csf therapies, the rising prevalence of chemotherapy-induced neutropenia, an expanding oncology patient population, regulatory approvals for first-generation g-csf products, and the adoption of injectable formulations.
The market for g-csf (granulocyte colony stimulating factors) is projected to experience substantial expansion over the upcoming years. Its valuation is set to reach $12.21 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. This anticipated growth is driven by factors such as the introduction of innovative g-csf products, the widening presence of biosimilars in developing markets, an increase in combination therapy applications, a growing preference for pre-filled syringe formats, and enhanced investment in supportive care and programs for neutropenia management. Key trends foreseen during this period encompass an escalating demand for g-csf biosimilars, a greater uptake of pre-filled syringes and injectable options, an increase in combination treatments involving other growth factors, broader application of g-csf in oncology and blood disorder therapies, and heightened understanding of neutropenia management and supportive care.
Get A Free Sample Report With In-Depth Market Insights:
G-CSF (Granulocyte Colony Stimulating Factors) Market Growth Momentum: What Factors Are Shaping Demand?
The G-CSF (granulocyte colony stimulating factor) market is anticipated to expand due to the rising incidence of cancer. Cancer is defined as an illness marked by the unchecked proliferation and dissemination of atypical cells, capable of impairing normal bodily functions and causing mortality. This growing prevalence of cancer stems from factors like an aging demographic, shifts in lifestyle, and environmental exposures that elevate the risk of developing the disease. The G-CSF market addresses this trend by offering growth factors that encourage the production of white blood cells, thereby lowering the chances of infection and sepsis in individuals with cancer receiving chemotherapy. For example, data from October 2025, provided by the National Health Service (NHS), a UK government health agency, reported 354,820 new cancer diagnoses in 2023, averaging 972 daily, which represents an increase of 8,605 compared to 2022. Consequently, the expanding incidence of cancer is stimulating the growth within the G-CSF (granulocyte colony stimulating factor) market.
G-CSF (Granulocyte Colony Stimulating Factors) Market Breakdown By Product Type And Application
The g-csf (granulocyte colony stimulating factors) market covered in this report is segmented –
1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types
2) By Product Form: Tablet, Capsule, Other Product Forms
3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications
Subsegments:
1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim
2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies
3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim
4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors
G-CSF (Granulocyte Colony Stimulating Factors) Market Trends Redefining Industry Growth
Companies operating within the G-CSF (granulocyte colony stimulating factor) market are concentrating on technological breakthroughs in hematopoietic treatments, including dimeric fusion protein design, to enhance neutrophil production and mitigate immunogenicity in long-acting G-CSF therapies. Dimeric fusion protein design signifies the linkage of two G-CSF molecules into a singular protein to extend its half-life and improve receptor activation without PEGylation. As an illustration, in November 2023, Evive Biotech Inc., a biopharmaceutical company based in Singapore, secured U.S. Food and Drug Administration (FDA) approval for Ryzneuta (efbemalenograstim alfa), which is a long-acting biosimilar G-CSF intended for reducing the length of neutropenia and febrile neutropenia in adults undergoing cytotoxic chemotherapy. Ryzneuta, a modified recombinant G-CSF, works by stimulating neutrophil creation in the bone marrow, thereby accelerating the recovery of neutrophil counts. Its significant attributes encompass long-acting administration, compatibility with numerous chemotherapy regimens, and a ready-to-use prefilled syringe. It is employed for the prevention of chemotherapy-induced neutropenia, mobilization of stem cells, and supportive care for immunocompromised patients, providing benefits such as fewer injections, better adherence, and superior overall patient results.
G-CSF (Granulocyte Colony Stimulating Factors) Market Company Landscape And Competitive Strategy
Major companies operating in the g-csf (granulocyte colony stimulating factors) market are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, Cipla.
View The Full G-CSF (Granulocyte Colony Stimulating Factors) Market Report:
G-CSF (Granulocyte Colony Stimulating Factors) Market Top Region By Revenue And Market Share
North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2025. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
